Ginseng-notoginseng Containing Supplement for Chronic Fatigue
Efficacy and Safety of Ginseng-notoginseng Containing Supplement on Chronic Fatigue in Adults: A Randomized Waitlist-controlled Trial
This study aims to find out whether a dietary supplement containing ginseng and notoginseng (GIN-201) can safely reduce persistent fatigue in adults. Chronic fatigue is a lasting feeling of tiredness that rest does not relieve which affects about 10% of adults in Hong Kong and can harm sleep, thinking, and quality of life. Ginseng and notoginseng are traditional Chinese medicine herbs thought to boost energy, and early research suggests they may help with fatigue, but their combined effect has not been tested in people.
The study will recruit 130 adults aged 30 to 75 who report fatigue and poor sleep. Participants will be randomly assigned to one of two groups: one group takes GIN-201 capsules (4 per day) for 6 weeks, while the other group waits 6 weeks before starting the same supplement. Both groups will then be followed for another 6 weeks. Fatigue, sleep, mood, quality of life, and sexual/menopausal symptoms will be measured with standard questionnaires, and blood tests will check for markers of inflammation, stress, aging, and mitochondrial health, as well as for safety.
The main question the study is trying to answer is: Does taking GIN-201 for 6 weeks reduce fatigue more than no treatment, and is it safe? The researchers hypothesize that GIN-201 will reduce fatigue in adults with persistent fatigue. The study will also explore whether changes in blood biomarkers are linked to any benefits, which may help identify who is most likely to respond to the supplement.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Yunqing Xun
- Número de teléfono: +852 5229 5427
Copia de seguridad de contactos de estudio
- Nombre: Tung Leong Fong
- Número de teléfono: +852 56604020
- Correo electrónico: u3557512@connect.hku.hk
Ubicaciones de estudio
-
-
Abia State
-
Calabar, Abia State, Nigeria, 540221
- Specialist Clinical Centre for Teaching and Research, School of Chinese Medicine, The University of Hong Kong
-
Contacto:
- TUNG LEONG FONG
- Número de teléfono: +852 5660 4020
- Correo electrónico: tlfong@hku.hk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Ages 30 to 75 years
- Self-reported fatigue with Chalder Fatigue Scale ≥4
- Self-reported poor sleep quality with Pittsburgh Sleep Quality Index >5
- Able to complete an online validated fatigue survey, 6-week intervention, and all follow-ups
Exclusion Criteria:
- Diagnosed with dementia or major psychiatric disorder
- Sleep apnea requiring CPAP
- Current participation in other trials
- Unable to comply with study procedures and give informed consent
- Known allergy to study product or its excipients
- Abnormal heart, liver or renal function
- Not pregnant or planning pregnancy within 6 months
- Using anticoagulants
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: GIN-201 supplement
Participants receive Ginseng-notoginseng Containing Supplement (GIN-201) in 4 capsules, once per day, for 6 weeks, according to the manufacturer's guidelines, followed by a 6-week follow-up. |
GIN-201 is a capsule supplement produced via microbial fermentation technology in a GMP-certified Hong Kong facility, converting ginseng and notoginseng into a highly bioavailable extract; It is reported to support mitochondrial function, DNA repair, NAD+ elevation, and antioxidant defense. Participants take 4 capsules orally once daily for 6 weeks, followed by a 6-week follow-up. |
|
Sin intervención: waitlist group
The waiting list control group will wait for 6 weeks after the randomization, and then start to receive GIN-201 in 4 capsules, once per day, for 6 weeks, followed by a 6week follow-up. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Chalder Fatigue Score (CFS)
Periodo de tiempo: From enrollment to 6 weeks
|
Bimodally scored 0-4 on an 11-item scale; higher scores indicate greater fatigue. |
From enrollment to 6 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Chalder Fatigue Score (CFS)
Periodo de tiempo: From enrollment to 6 weeks and 12 weeks
|
Bimodally scored 0-4 on an 11-item scale; higher scores indicate greater fatigue. |
From enrollment to 6 weeks and 12 weeks
|
|
Fatigue Severity Score (FSS)
Periodo de tiempo: From enrollment to 6 weeks and 12 weeks
|
Likert score 1-7 on a 9-item scale; higher scores indicate more severe fatigue. |
From enrollment to 6 weeks and 12 weeks
|
|
PROMIS Short Form Fatigue 7A
Periodo de tiempo: From enrollment to 6 weeks and 12 weeks
|
5-point Likert scale across 7 items; higher scores indicate greater fatigue. |
From enrollment to 6 weeks and 12 weeks
|
|
36-Item Short-Form Health Survey (SF-36)
Periodo de tiempo: From enrollment to 6 weeks and 12 weeks
|
Range 0-100; higher scores indicate better health status. |
From enrollment to 6 weeks and 12 weeks
|
|
Hospital Anxiety and Depression Scale (HADS)
Periodo de tiempo: From enrollment to 6 weeks and 12 weeks
|
Range 0-21; higher scores indicate more severe symptoms. |
From enrollment to 6 weeks and 12 weeks
|
|
Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: From enrollment to 6 weeks and 12 weeks
|
Range 0-21; higher scores indicate worse sleep quality. |
From enrollment to 6 weeks and 12 weeks
|
|
Brief Male Sexual Function Inventory (BMSFI) / Menopause Rating Scale (MRS)
Periodo de tiempo: From enrollment to 6 weeks and 12 weeks
|
BMSFI: 11-item in 5 divisions; higher score indicates more satisfied sexual function (men). MRS: Likert score 0-4 for 11 items; higher indicates severer menopause symptoms (women). |
From enrollment to 6 weeks and 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- UW-26-299
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data underlying the results reported in the primary study publication will be shared, together with a data dictionary. Shared data will include participant characteristics, treatment allocation, Chalder Fatigue Score and other fatigue questionnaire scores, quality-of-life (SF-36), psychological (HADS), sleep (PSQI), and sexual/menopausal symptom (BMSFI/MRS) scores, biomarker results (inflammation, stress, neurotrophic, aging, and mitochondrial health), adherence data, and adverse event data used in the published analyses. Direct identifiers and the participant identification linkage file will not be shared. Access will be provided to qualified researchers following approval of a research proposal and execution of a data use agreement. Sharing will be subject to any required Institutional Review Board (IRB) and institutional approvals and must be consistent with participant consent.
Marco de tiempo para compartir IPD
De-identified individual participant data and the selected supporting documents will be available from publication of the primary study results until five years after study completion.
Criterios de acceso compartido de IPD
De-identified individual participant data underlying the published results, the data dictionary, and the selected supporting documents will be available to qualified researchers upon reasonable request. Requests should be submitted by email to the principal investigator and include a methodologically sound research proposal and statistical analysis plan. The principal investigator will review requests for scientific merit, feasibility, and consistency with participant consent and institutional requirements. Approved researchers may use the data only for analyses specified in the approved proposal. Access will require a signed data use agreement and any necessary IRB and institutional approvals. Data will be provided through secure transfer.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CÓDIGO_ANALÍTICO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .